1. Eid, MA, Mehta, KS, Goodney, PP. Epidemiology of peripheral artery disease. Semin Vasc Surg 2021; 34: 38–46.
Google Scholar | Crossref | Medline2. Welten, GMJM, Schouten, O, Hoeks, SE, et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 2008; 51: 1588–1596.
Google Scholar | Crossref | Medline | ISI3. Anand, SS, Caron, F, Eikelboom, JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the compass trial. J Am Coll Cardiol 2018; 71: 2306–2315.
Google Scholar | Crossref | Medline4. McClure, GR, Chan, N, Kaplovitch, E, et al. Prevention and management of urgent/emergent limb Ischemia. Curr Cardiol Rep 2021; 23: 41.
Google Scholar | Crossref | Medline5. Zhang, X, Xing, L, Jia, X, et al. Comparative lipid-lowering/increasing efficacy of 7 statins in patients with dyslipidemia, cardiovascular diseases, or diabetes mellitus: systematic review and network meta-analyses of 50 randomized controlled trials. Cardiovasc Ther 2020; 2020: 3987065.
Google Scholar | Crossref | Medline6. Tsai, S, Vega, GL. Coronary and peripheral artery plaques: do differences in plaque characteristics translate to differences in lipid management? J Invest Med 2020; 68: 1141–1151.
Google Scholar | Crossref | Medline7. Cannon, CP, Blazing, MA, Giugliano, RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. New Engl J Med 2015; 372: 2387–2397.
Google Scholar | Crossref | Medline | ISI8. Sabatine, MS, Giugliano, RP, Keech, AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New Engl J Med 2017; 376: 1713–1722.
Google Scholar | Crossref | Medline | ISI9. Mohler, ER, Hiatt, WR, Creager, MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108: 1481–1486.
Google Scholar | Crossref | Medline | ISI10. Spring, S, Simon, R, van der Loo, B, et al. High-dose atorvastatin in peripheral arterial disease (PAD): effect on endothelial function, intima-media-thickness and local progression of PAD. An open randomized controlled pilot trial. Thromb Haemost 2008; 99: 182–189.
Google Scholar | Crossref | Medline11. Heart Protection Study Collaborative Group . Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 2007; 45: 645–654.
Google Scholar | Crossref | Medline | ISI12. Bonaca, MP, Nault, P, Giugliano, RP, et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk). Circulation 2018; 137: 338–350.
Google Scholar | Crossref | Medline13. Schwartz, GG, Steg, PG, Szarek, M, et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by Alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation 2020; 141: 1608–1617.
Google Scholar | Crossref | Medline14. Pastori, D, Farcomeni, A, Milanese, A, et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 2020; 120: 866–875.
Google Scholar | Crossref | Medline15. Kokkinidis, DG, Arfaras-Melainis, A, Giannopoulos, S, et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis. Vasc Med 2020; 25: 106–117.
Google Scholar | SAGE Journals | ISI16. Alkhalil, M, Kuzemczak, M, Whitehead, N, et al. Meta-analysis of intensive lipid-lowering therapy in patients with polyvascular disease. J Am Heart Assoc 2021; 10: e017948.
Google Scholar | Crossref | Medline17. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
Google Scholar | Crossref | Medline18. Sterne, JAC, Savović, J, Page, MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: l4898.
Google Scholar | Crossref | Medline19. Viechtbauer, W . Conducting meta-analyses in R with the metaphor package. J Stat Softw 2010; 36: 1–48.
Google Scholar | Crossref | ISI20. Rymer, JA, Swaminathan, RV, Aday, AW, et al. The current evidence for lipid management in patients with lower extremity peripheral artery disease: what is the therapeutic target? Curr Cardiol Rep 2021; 23: 13.
Google Scholar | Crossref | Medline21. Aboyans, V, Ricco, JB, Bartelink, MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) the task force for the diagnosis and treatment of peripheral arterial diseases of the European society of cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763–816.
Google Scholar | Crossref | Medline22. Bonaca, MP, Gutierrez, JA, Cannon, C, et al. Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. Lancet Diabetes Endocrinol 2018; 6: 934–943.
Google Scholar | Crossref | Medline23. Westin, GG, Armstrong, EJ, Bang, H, et al. Association between statin medications and mortality, major adverse cardiovascular events, and amputation-free survival in patients with critical limb ischemia. J Am Coll Cardiol 2014; 63: 682–690.
Google Scholar | Crossref | Medline | ISI24. Stavroulakis, K, Borowski, M, Torsello, G, et al. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg 2017; 66: 1534–1542.
Google Scholar | Crossref | Medline25. Conte, MS, Bradbury, AW, Kolh, P, et al. Global vascular guidelines on the management of chronic limb-threatening Ischemia. Eur J Vasc Endovasc Surg 2019; 58: S1–S109.e33.
Google Scholar | Crossref | Medline26. Stoekenbroek, RM, Boekholdt, SM, Fayyad, R, et al. High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. Heart 2015; 101: 356–362.
Google Scholar | Crossref | Medline | ISI27. Subherwal, S, Patel, MR, Kober, L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation 2012; 126: 1345–1354.
Google Scholar | Crossref | Medline | ISI28. McBride, CL, Akeroyd, JM, Ramsey, DJ, et al. Statin prescription rates and their facility-level variation in patients with peripheral artery disease and ischemic cerebrovascular disease: insights from the department of veterans affairs. Vasc Med 2018; 23: 232–240.
Google Scholar | SAGE Journals | ISI29. Blacher, J, Cacoub, P, Luizy, F, et al. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg 2006; 44: 314–318.
Google Scholar | Crossref | Medline | ISI30. Poussa, H, Strandberg, TE, Tikkanen, I, et al. Diagnosis and treatment of dyslipidemia are neglected in patients with peripheral artery disease. Scand Cardiovasc J 2007; 41: 138–141.
Google Scholar | Crossref | Medline31. Bluro, IM, Rossi, E, Lucas, L, et al. LDL cholesterol targets in patients undergoing peripheral revascularization. Rev Argent Cardiol 2017; 85: 205–209.
Google Scholar32. Arya, S, Khakharia, A, Binney, ZO, et al. Association of statin dose with amputation and survival in patients with peripheral artery disease. Circulation 2018; 137: 1435–1446.
Google Scholar | Crossref | Medline33. Behroozian, A, Beckman, JA. Microvascular disease increases amputation in patients with peripheral artery disease. Arterioscler Thromb Vasc Biol 2020; 40: 534–540.
Google Scholar | Crossref | Medline34. Dhatariya, K, Bain, SC, Buse, JB, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care 2018; 41: 2229–2235.
Google Scholar | Crossref | Medline35. Althouse, AD, Abbott, JD, Sutton-Tyrrell, K, et al. Favorable effects of insulin sensitizers pertinent to peripheral arterial disease in type 2 diabetes: results from the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. Diabetes Care 2013; 36: 3269–3275.
Google Scholar | Crossref | Medline